If the primary endpoint is not survival, but there is a survival benefit observed, how much does that matter? How large should a randomized trial be to justify approval? Which experts should evaluate new cancer therapies and comment on their suitability for approval? Who has the responsibility of protecting men and women who make regulatory decisions that are unpopular? How do we measure conflicts of interests and exclude those with real or apparent conflicts from the regulatory process? How much correlative science is required to create a sense of trust in clinical results? Should response rates and progression rates correlate with survival? Did the control group do worse than expected? How much can (or should) our society pay for incremental progress? Are we now reaching limits in terms of what we can afford to pay for new therapies? What are the ramifications and consequences if our society decides that some drugs are too expensive to provide? Although the FDA's ability to mandate post-marketing trials is unquestioned, who should be authorized to question the wisdom of their trial designs? Is this drug development or drama? Actually it is a touch of both. Some of these questions I will touch on and some I will not. For now, space constraints require only a handful of these issues be addressed in relationship to sipuleucel-T.
Let us start with the science and how scientific understanding led to a new medicine. Dranoff and colleagues demonstrated [2] in 1993 that granulocyte-monocyte colony stimulating factor (GM-CSF), when expressed in tumor cells, can inhibit cancerous growth in certain model systems. This fundamentally important observation led to experiments that combined GM-CSF and prostatic acid phosphatase to form a fusion protein that in turn is used to generate immune responses. This concept was scaled-up and applied to humans with prostate cancer. Large clinical trials have now led to a new FDA approval in the USA. This approval, in March 2010, was the first FDA approval for advanced prostate cancer since 2004. Sipuleucel-T was only the second agent in history to be associated with a survival benefit for metasta tic castrate-resistant prostate cancer (mCRPC).
npg Randomized trials in patients with mCRPC patients with minimal or no symptoms demonstrated a 4.1 month survival benefit for sipuleucel-T over 'control' treated patients. This large randomized trial (IMPACT or D9902B) with 512 patients was recently published in the New England Journal of Medicine [3] . The trial confirmed the survival benefit observed in smaller earlier trials (D9901) and served as an appropriate basis for the FDA approval.
Is the survival advantage in the IMPACT trial due to a poorly performing control group? No, survival in the control arm for IMPACT (21.7 months) was nearly identical to that previously observed [4] for asymptomatic mCRPC patients treated in the control group of the large atrasentan trial (20.3 months).
In IMPACT, no response rate or progression-free survival (PFS) advantage was seen for sipuleucel-T over the control group. Is our cur rent process of measuring response and progression truly flawed, or do post-progression alterations in tumor growth kinetics account for the interesting survival advantages observed? Clearly postprogression delays in growth are a possible explanation but this remains a hypothesis rather than fact (at this time). Does every trial with this class of agents now depend on analysis of overall survival (OS)? If both responses and PFS are unreliably measured, are there any other intermediate endpoints that can serve as an index of sipuleucel-T activity? The conundrum of PFS and survival being delinked is now becoming a familiar story in mCRPC. In a large randomized phase III trial, satraplatin/ prednisone had a PFS but not OS advantage over prednisone alone [5] . Similar findings with regard to PFS and OS were reported for bevacizumab/docetaxel/prednisone as compared to docetaxel/prednisone [6] . Randomized phase II studies with OGX-011 [7] and ZD4054 [8] have been associated with OS but not PFS improvements. Have we been deluding ourselves for years when evaluating PFS, or are the new agents different to the old ones? There is clearly more we need to understand about markers of progression in mCRPC.
Now that survival advantages with sipuleucel-T are demonstrated, the FDA has approved the drug, and patients are clamoring for this novel treatment that has a bit of panache; what is the next step? Ordinarily the next step would focus on new indications (such as earlier stage prostate cancer), or new therapeutic combinations (e.g. ipilumimab plus sipuleucel-T comes to mind). However this usual discussion has been subverted by the price of therapy. The sponsor (Dendreon) has decreed that centers administering the drug will be billed $93 000 for the three infusions required for therapy. Costs to the patient and their insurance companies will be considerably more after administration and other costs are calculated. How is such a price justified? For that matter how is the cost of any new drug in the USA determined and justified? Do we need to re-think the current process and focus discussion on why medical care in the USA consumes a greater percentage of the gross domestic product (GDP) as compared to any other nation? Is now the time to do so?
The debate on costs involves many stakeholders and the consequences are large. Investment in new products is fueled by the expectation of profitable returns and if poor returns on investment become an expectation, then new progress against dreaded disease will not be forthcoming. The USA has marvelous medical techno logy and breath-taking costs but the lifespan of our citizens is not longer than our peers. How this debate is resolved will be key to the future of both medicine and the global economy. 
